COVID-19–related skin manifestations: Update on therapy

Atzori, Laura; Recalcati, Sebastiano; Ferreli, Caterina; Hoenig, Leonard J.; Rongioletti, Franco

doi:10.1016/j.clindermatol.2020.12.003

Cited by 13 publications

(24 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a correct differential diagnosis, patients should be evaluated for respiratory symptoms, fever, and petechial lesions [41]. Treatment of these cutaneous eruptions includes therapy with topical corticosteroids in mild cases and systemic corticosteroids in more severe or generalized involvement [42].…”

Section: Rashes With Petechiae/purpuramentioning

confidence: 99%

“…In addition, chilblains could be a paraviral rash associated with COVID-19 [45]. Although these lesions tend to resolve spontaneously in 1 to 4 weeks, topical corticosteroid therapy alone or in combination with topical antibiotics has been proposed as a treatment for chilblain-like lesions [42].…”

Section: Acral Lesionsmentioning

confidence: 99%

“…Most urticarial lesions may not be very useful for the diagnosis of COVID-19, because the pathways are unclear either these urticarial eruptions represent a manifestation of SARS-CoV-2 itself by direct mast cell degranulation [12] or are induced by drugs associated with COVID-19 treatment [22,31]. Urticaria has been described as a side effect of many drugs used for the treatment of COVID-19, such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir [52], albeit some patients' urticaria improved without discontinuation of treatment against SARS-CoV-2 infection [42,50]. Treatment of these lesions includes lowdose systemic corticosteroid therapy combined with antihistamines, not only to control urticaria but also to improve morbidity and mortality from SARS-CoV-2 disease.…”

Section: Urticarial Eruptionmentioning

confidence: 99%

“…Treatment of these lesions includes lowdose systemic corticosteroid therapy combined with antihistamines, not only to control urticaria but also to improve morbidity and mortality from SARS-CoV-2 disease. The administration of corticoids requires individual guidelines, and the duration should be as short as possible until the suppression of symptoms [42].…”

Section: Urticarial Eruptionmentioning

confidence: 99%

See 3 more Smart Citations

Identification, Mechanism, and Treatment of Skin Lesions in COVID-19: A Review

Fernández-Lázaro

Garrosa

2021

Viruses

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a multisystem disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that primarily causes respiratory symptoms. However, an increasing number of cutaneous manifestations associated with this disease have been reported. The aim of this study is to analyze the scientific literature on cutaneous manifestations associated with SARS-CoV-2 by means of a narrative literature review until June 2021. The search was conducted in the following electronic databases: Medline (PubMed), SciELO, and Cochrane Library Plus. The most common cutaneous manifestations in patients with COVID-19 are vesicular eruptions, petechial/purpuric rashes, acral lesions, liveoid lesions, urticarial rash, and maculopapular-erythematous rash. These manifestations may be the first presenting symptoms of SARS-CoV-2 infection, as is the case with acral lesions, vesicular eruptions, and urticaria. In relation to severity, the presence of liveoid lesions may be associated with a more severe course of the disease. Treatment used for dermatological lesions includes therapy with anticoagulants, corticosteroids, and antihistamines. Knowledge of the dermatologic manifestations associated with SARS-CoV-2 contributes to the diagnosis of COVID-19 in patients with skin lesions associated with respiratory symptoms or in asymptomatic patients. In addition, understanding the dermatologic lesions associated with COVID-19 could be useful to establish a personalized care plan.

show abstract

Section: Rashes With Petechiae/purpuramentioning

confidence: 99%

Section: Acral Lesionsmentioning

confidence: 99%

Section: Urticarial Eruptionmentioning

confidence: 99%

Section: Urticarial Eruptionmentioning

confidence: 99%

See 2 more Smart Citations

Identification, Mechanism, and Treatment of Skin Lesions in COVID-19: A Review

Fernández-Lázaro

Garrosa

2021

Viruses

View full text Add to dashboard Cite

show abstract

“… 70 This condition, which is of vasculitic origin, is presented with mucocutaneous involvement, including polymorphic eruptions, palmar and plantar erythema, and other Kawasaki disease features. 71 …”

Section: Covid‐19 Skin Involvement In Childrenmentioning

confidence: 99%

Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge

Afshar

Babazadeh

Hasanpour

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has become a significant health problem globally. The virus has spread widely and become a global pandemic. The pathophysiology for SARS‐CoV‐2 has not been explained clearly. It has been associated with several multiorgan symptoms, among which its dermatological manifestations are of great interest. Primarily, there has been no report of skin features among COVID‐19 patients. Nevertheless, recently there have been several reports regarding COVID‐19 patients who presented with cutaneous manifestations. In the current review, we focus on the various cutaneous manifestations of COVID‐19 infection.

show abstract